Navigation Links
Caldera Pharmaceuticals Announces Closing of Financing
Date:9/11/2013

titutions and other Wall Street firms because they cannot invest enough capital in each situation to justify the expense of investigating these companies. Our focus and high energy level allow us to exploit these inefficiencies, giving us the added advantage needed to prosper in the microcap market.

Company Contact:

Gary Altman, CEO

galtman@XRpro.com

Investor Contact:

Aimee Boutcher

Aimee@XRpro.com

973 332-0121

This release includes forward-looking statements on the Company's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the expected contribution of Mr. Altman and our technology. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in the Company's forward-looking statements include, among others, our ability to sell and market our technology and services, the contribution and integration of the Company's new management and the other factors described in the Company's Report on Form 10-K for the year ended December 31, 2012 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements con
'/>"/>

SOURCE Caldera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und ... , Ziel der Zusammenarbeit ... Basis genomischer Daten aus Plasmaproben zur Steuerung von ... eingesetzt werden kann  Neuer Bluttest basiert ... Kit und soll auf Rotor-Gene Q, einer Automationsplattform ...
(Date:7/27/2014)... July 27, 2014 /PRNewswire-iReach/ -- This is ... Global and Chinese Vardenafil (CAS 224785-90-4) industry. ... of Vardenafil (CAS 224785-90-4) including its classification, ... explores global and China,s top manufacturers of ... capacity, production value, cost, gross margin and ...
(Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
(Date:7/28/2014)... one of the UK,s most common respiratory diseases has ... disease (COPD) is the name for a collection of ... to the lungs. Often linked to smoking, it ... admissions in the UK, with a high proportion of ... , A team of researchers, led by ...
(Date:7/28/2014)... Modesto, CA (PRWEB) July 28, 2014 At ... an uncomfortable situation where they’re forced to contact the authorities. ... little more difficult than it initially seems. , Not every ... a vehicle get stolen, a person get mugged, or a ... little less obvious, leading onlookers to be more passive than ...
(Date:7/28/2014)... Researchers from Boston University School of Medicine (BUSM) report ... the risk of developing Alzheimer,s disease (AD). The discovery ... drug treatment options that target PLXNA4 specifically. These findings ... AD is the most frequent age-related dementia affecting 5.4 ... and older, and more than 40 percent of people ...
(Date:7/28/2014)... 28, 2014 Qualis Health, one ... management organizations, has published a complimentary, online toolkit ... engaging patients and families in infection control. ... hospitals, the toolkit provides a step-by-step roadmap for ... and their families early in a hospital stay. ...
(Date:7/28/2014)... The North America Carotenoids & Antioxidants Market ... North America with analysis and forecast of revenue. This market ... to $812.7 million by 2018, at a CAGR of 7.1% ... the North America Carotenoids & Antioxidants Market report to get ... a glimpse of the segmentation in the market, and is ...
Breaking Medicine News(10 mins):Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Researchers identify potential biomarker for AD 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4
... Scientists at Warwick Medical School have uncovered the molecular ... ,health checkpoint, with cells that carry unequal numbers of ... , Studying simple yeast cells, scientists now understand the ... the correct number of chromosomes. , Most ...
... State University will lead a four-year, $5 million expanded ... discover proteins, or biomarkers, to help predict cardiovascular disease ... type 2 diabetes. Nearly 26 million Americans have ... U.S. The disease is a major cause of heart ...
... , TUESDAY, Nov. 1 (HealthDay News) -- Multiple sclerosis ... aim at the abnormal behavior of a specific type of ... the cells in question -- known as "B cells" -- ... and disabling nervous system disease, commonly called MS. The ...
... high school students are considered overweight, and while a myriad ... parents can do to help curb these rates, very little ... lose weight. Research led by public health doctoral candidate ... Philadelphia report wanting to lose weight, their actions are more ...
... an eight hour shift leads to substantial cost savings and energy ... Journal of the American College of Radiology . ... the use of computers and scanning equipment. "We should ... this equipment and look for ways to reduce it, both as ...
... NYU Langone Medical Center identified for the first time that ... outer and inner layers of the brain, called "blurring", may ... development of new therapies for degenerative brain conditions, such as ... issue of the Journal of Neuroscience . ...
Cached Medicine News:Health News:Warwick scientists discover how daughter cells receive the same number of chromosomes 2Health News:ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment 2Health News:ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment 3Health News:New Multiple Sclerosis Therapy Promising in Early Trial 2Health News:New Multiple Sclerosis Therapy Promising in Early Trial 3Health News:Study finds overweight teens want to lose weight, going about it the wrong way 2Health News:Neurologists identify potential biomarker of cognitive decline for earlier diagnosis of disease 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: